Resiliency in Total Joint Arthroplasty

Overview

The investigators primary objective is to determine how does participation in StreaMD affect patient reported outcomes after Total Hip Arthroplasty (THA) or Total Knee Arthroplasty (TKA)?

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2025

Detailed Description

Osteoarthritis is a leading cause of disability in the US. By conservative estimates, about 54 million adults in the US have doctor-diagnosed arthritis. The number of people expected to have arthritis by the year 2040 is more than 78 million. Total joint arthroplasty is considered the treatment of choice for end-stage osteoarthritis. Currently, more than 1 million hip and knee replacements are performed each year in the US. By 2030, primary THR is projected to grow 171% and primary TKR is projected to grow by up to 189%, for a projected 635,000 and 1.28 million procedures, respectively. The incidence of pre-operative psychological distress in this group of patients is reported between 30% and 60% and preoperative psychological distress is associated with poorer pain and functional outcomes after surgery. Resilience, characterized by an ability to bounce back or recover from stress, is increasingly recognized as a psychometric property affecting many outcomes' domains including outcomes after TJA. Better resilience could improve patients overall satisfaction with the procedure.

Interventions

  • Other: StreaMD
    • Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.

Arms, Groups and Cohorts

  • No Intervention: Control
    • No other non-standard of care activities will be performed
  • Experimental: Intervention
    • Will be signed up for the automated text messaging program (StreaMD)

Clinical Trial Outcome Measures

Primary Measures

  • Patient Reported Outcome Score (PROMIS) following THA or TKA
    • Time Frame: Follow Up Visits up to 2-Years
    • Patient reported outcome will consist of the Patient-Reported Outcomes Measurement Information System (PROMIS)
  • Patient Reported Outcome Score (HOOS Jr.) following THA or TKA
    • Time Frame: Follow Up Visits up to 2-Years
    • Patient reported outcome will consist of the hip disability and osteoarthritis outcome score (HOOS Jr.)
  • Patient Reported Outcome Score (KOOS Jr.) following THA or TKA
    • Time Frame: Follow Up Visits up to 2-Years
    • Patient reported outcome will consist of the knee injury and osteoarthritis outcome score (KOOS Jr.)

Participating in This Clinical Trial

Inclusion Criteria

  • All patients aged 18 and older who are receiving a total hip or knee replacement.

Exclusion Criteria

  • Patients enrolled in the MyMobility study
  • Patients who do not have cell phones with text messaging capability
  • Non-English speaking patients

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Utah
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jeremy Gililland, Principle Investigator – University of Utah
  • Overall Official(s)
    • Jeremy Gililland, M.D., Principal Investigator, University of Utah

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.